Cinhyaluronate sodium

Drug Profile

Cinhyaluronate sodium

Alternative Names: Hyaluronic acid ophthalmic - Seikagaku Corporation; SI-614

Latest Information Update: 09 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seikagaku Corporation
  • Class Eye disorder therapies; Glycosaminoglycans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dry eyes

Most Recent Events

  • 02 Feb 2016 Phase-II/III clinical trials in Dry eyes in European Union before February 2016 (Ophthalmic) (Seikagaku Corporation pipeline, July 2016)
  • 02 Feb 2016 Phase II/III development is ongoing in USA (Seikagaku Corporation pipeline, July 2016)
  • 01 Jul 2014 Phase-II/III clinical trials in Dry eyes in USA (Ophthalmic) (NCT02205840)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top